Loading…
Prime Medicine, Inc. is projected to rise to $3.83 by 2027, a +16% move from its current price of $3.30. PRME is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.18 | $3.30 | $3.43 | +0.01% |
| May 30 | $3.13 | $3.30 | $3.48 | +0.02% |
| May 31 | $3.10 | $3.30 | $3.52 | +0.03% |
| Jun 1 | $3.06 | $3.30 | $3.56 | +0.03% |
| Jun 2 | $3.04 | $3.30 | $3.59 | +0.04% |
| Jun 3 | $3.01 | $3.30 | $3.62 | +0.05% |
| Jun 4 | $2.99 | $3.30 | $3.64 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.99 | $3.30 | $3.64 | +0.06% |
| Week 2 | $2.87 | $3.30 | $3.80 | +0.12% |
| Week 3 | $2.79 | $3.31 | $3.92 | +0.18% |
| Week 4 | $2.72 | $3.31 | $4.03 | +0.24% |
| Week 5 | $2.66 | $3.31 | $4.12 | +0.30% |
| Week 6 | $2.60 | $3.31 | $4.21 | +0.36% |
| Week 7 | $2.55 | $3.31 | $4.30 | +0.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prime Medicine, Inc. is a biotechnology company that engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic PM359 for Chronic Granulomatous Disease is in Phase 1/2; PM577 for Wilson Disease is in preclinical studies; and PM647 to treat a genetic disorder caused by mutations in the SERPINA1 gene.
The company also provides in vivo programs targeting diseases of the liver, and Cystic Fibrosis programs, and offers Prime Editing technology comprising a programmable DNA binding domain, such as Cas domains, typically modified to avoid a double-stranded break in the DNA, as well as an RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
It maintains research collaborations and license agreements with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam.
Prime Medicine, Inc. trades as PRME and operates in the Healthcare sector. The current price is $3.30 with a market cap of $596.04M and a rank of 2871. The stock’s price outlook is captured in a multi-year forecast that shows a rising path from 2026 through 2050, with 2026 avg $3.30, 2027 avg $3.83, 2028 avg $4.70, 2029 avg $4.63, 2030 avg $5.12, 2031 avg $5.04, 2032 avg $4.74, 2033 avg $5.55, 2034 avg $6.71, 2035 avg $7.43, 2040 avg $9.95, and 2050 avg $13.85.
The 30-day technical backdrop shows a range of $2.58 to $4.22, consistent with ongoing volatility.
A major floor 37.6% below — a decisive break under it would weaken the trend.
The nearest floor, 18.2% below — buyers have tended to step in here.
The nearest ceiling, 20.0% above — a clean break opens room to run.
A major ceiling 41.7% above — clearing it would confirm fresh momentum.
Key PRME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.00 | Buy | $3.06 | Buy |
| MA 10 | $2.99 | Buy | $3.06 | Buy |
| MA 20 | $3.17 | Buy | $3.17 | Buy |
| MA 50 | $3.43 | Sell | $3.39 | Sell |
| MA 100 | $3.65 | Sell | $3.57 | Sell |
| MA 200 | $3.98 | Sell | $3.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.25 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 38.87 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.80 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.69 | Sell |
| Awesome (5,34) | -0.40 | Sell |
| Ultimate (7,14,28) | 60.89 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.09 | Buy |
| ADX (14) | 20.17 | Buy |
| ATR (14) | 0.11 | Info |
The near-term technical picture is Neutral, with RSI14 at 50. The 50-day simple moving average sits at $3.43 and the 200-day simple moving average at $3.98, providing a trajectory that sits between support and resistance levels. Key support is at $2.70 and resistance at $3.96, shaping a tighter near-term range around the current price.
The 30-day price range spans $2.58 to $4.22, highlighting modest upside and downside potential over the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.70 | $3.30 | $4.01 | 0% | Neutral | |
| $2.93 | $3.83 | $5.36 | +16% | Neutral | |
| $3.46 | $4.70 | $6.89 | +43% | Bullish | |
| $3.30 | $4.63 | $7.04 | +40% | Bullish | |
| $3.55 | $5.12 | $8.02 | +55% | Bullish | |
| $3.40 | $5.04 | $8.11 | +53% | Bullish | |
| $3.12 | $4.74 | $7.81 | +44% | Bullish | |
| $3.56 | $5.55 | $9.34 | +68% | Bullish | |
| $4.21 | $6.71 | $11.51 | +103% | Bullish | |
| $4.56 | $7.43 | $12.99 | +125% | Bullish | |
| $5.51 | $9.95 | $18.75 | +202% | Bullish | |
| $6.36 | $13.85 | $29.07 | +320% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.70 | $3.30 | $3.88 | +0.00% |
| June 2026 | $2.79 | $3.31 | $4.03 | +0.23% |
| July 2026 | $2.78 | $3.33 | $4.12 | +0.54% |
| August 2026 | $2.59 | $3.13 | $3.93 | -5.93% |
| September 2026 | $2.47 | $3.01 | $3.82 | -3.86% |
| October 2026 | $2.54 | $3.11 | $4.00 | +3.54% |
| November 2026 | $2.55 | $3.14 | $4.07 | +1.00% |
| December 2026 | $2.47 | $3.07 | $4.01 | -2.47% |
Click any year to see its month-by-month PRME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PRME to range from $2.70 to $4.01 through 2026. The $3.30 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PRME price prediction for 2027 points to an average of $3.83 (low $2.93, high $5.36) — a potential gain of +16% on today's $3.30. Price action looks broadly range-bound.
In 2028, PRME is projected to trade between $3.46 and $6.89, averaging $4.70 — a potential gain of +43% from today's $3.30. That is up +23% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Prime Medicine, Inc.'s 2029 outlook centres on $4.63, within a $3.30 to $7.04 range. That is -2% versus the projected 2028 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2030, PRME could reach as high as $8.02, with a base case around $5.12 and support toward $3.55 — roughly +55% from $3.30. Buyers look set to stay in control over this stretch.
Expect PRME to range from $3.40 to $8.11 through 2031. The $5.04 average target implies a +53% move from current prices. That is -2% versus the projected 2030 average. Momentum favours further upside here.
The PRME price prediction for 2032 points to an average of $4.74 (low $3.12, high $7.81) — a potential gain of +44% on today's $3.30. Buyers look set to stay in control over this stretch.
In 2033, PRME is projected to trade between $3.56 and $9.34, averaging $5.55 — a potential gain of +68% from today's $3.30. That is up +17% on the projected 2032 average. Momentum favours further upside here.
Prime Medicine, Inc.'s 2034 outlook centres on $6.71, within a $4.21 to $11.51 range. That is up +21% on the projected 2033 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PRME could reach as high as $12.99, with a base case around $7.43 and support toward $4.56 — roughly +125% from $3.30. Momentum favours further upside here.
Expect PRME to range from $5.51 to $18.75 through 2040. The $9.95 average target implies a +202% move from current prices. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PRME price prediction for 2050 points to an average of $13.85 (low $6.36, high $29.07) — a potential gain of +320% on today's $3.30. Momentum favours further upside here.
Investing $1,000 in PRME today (≈ 303.030303 PRME) could be worth
$4,196.51
+$3,196.51 (+320%) by 2050 · US Dollar
Based on the average projected PRME price of $13.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRMEwould be worth at today's price.
$1,000 invested in PRME on May 27, 2025 (≈ 787.401587 PRME) would be worth
$2,598.43
+$1,598.43 (+159.8%) today · 2.60× · US Dollar
Based on a PRME entry price of $1.27 vs. today's $3.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.83 | $1,166.08 | +16.6% |
| 1 month ago | $3.67 | $899.18 | -10.1% |
| 3 months ago | $4.38 | $753.42 | -24.7% |
| 6 months ago | $3.82 | $863.87 | -13.6% |
| 1 year ago | $1.27 | $2,598.43 | +159.8% |
| All time (3.6y) ago | $15.37 | $214.7 | -78.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRME forecast.
Our base-case forecast reaches $6.60 around 2034.
Implied market cap at $6.60: $1.19B
The multi-year forecast paints a bullish long-run arc. For 2026 the min/avg/max targets are $2.70, $3.30, and $4.01, with an ROI of 0 and a Neutral sentiment. By 2027 the path continues higher to an average of $3.83 with an ROI of 16.
In 2028 the forecast climbs to an average of $4.70 (ROI 42.5) and in 2029 to $4.63 (ROI 40.4), underpinning a sustained uphill trajectory. The 2030 target shows an average of $5.12 with ROI 55.2, followed by 2031 at $5.04 (ROI 52.8) and 2032 at $4.74 (ROI 43.7). By 2033 the average target is $5.55 (ROI 68.3) and 2034 is $6.71 (ROI 103.3), with 2035 at $7.43 (ROI 125.3).
The long horizon extends to 2040 with an average of $9.95 (ROI 201.7) and 2050 with an average of $13.85 (ROI 319.6). These numbers imply a rising price trajectory and a meaningful long-term appreciation potential, while the forecast remains an estimate and not a guarantee. Risks include the inherent uncertainty in development timelines and market dynamics, and the high volatility reflected in the near-term technical picture.
Tap a question to reveal the answer.
The forecast shows an average target of $5.12 for 2030 with an ROI of 55.2. The 2030 min and max are $3.55 and $8.02, respectively.
Near-term signals are Neutral with a current price of $3.30 and a 30-day range of $2.58 to $4.22. The forecast suggests a bullish long-term path, with the average rising to $13.85 by 2050 and a growing ROI across the years (e.g., 16% in 2027 and 319.6 in 2050). These are estimates and not guarantees.
The 2040 average target is $9.95, and the 2050 average target is $13.85, indicating the trajectory crosses near $10 closer to the latter horizon rather than by 2040.
Current price is $3.30 and market cap is $596.04M.
RSI 14 is 50, with SMA50 at $3.43 and SMA200 at $3.98. Support is at $2.70 and resistance at $3.96, and the 30-day price range is $2.58 to $4.22.
Prime Medicine, Inc. Community Discussion
0Share your Prime Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.